L ung cancer is the leading cause of cancer deaths worldwide, including Taiwan. 1, 2 In the 90s, more than 50% of patients with advanced non-small cell lung cancer (NSCLC) at diagnosis were older than 65 years. 3 According to the surveillance, epidemiology, and end results data in the United States, the median age of patients with lung cancer is 71 years (70 years for men and 71 years for women). 4 In Taiwan, the median age of patients with lung cancer is 71 years for men and 68 years for women. 5 Lung cancer has become a disease of the elderly.
For elderly patients, deterioration in cardiovascular and pulmonary functions may be the major concerns while considering curative surgery and radiotherapy. The decline of drug metabolizing capability and reduced bone marrow, liver, and renal functional reserves may limit the use of chemotherapy. 6 Thus, the optimal treatment for lung cancer in elderly patients may be different from those in younger patients.
In most clinical trials for lung cancer, there is a significant underrepresentation of elderly patients. [7] [8] [9] The elderly specific studies for lung cancer are relatively few. Data for elderly patients usually come from subset analyses of largescale clinical trials. A review reported that selected elderly patients with local and locally advanced lung cancer could tolerate surgery, radiotherapy, and chemoradiation. 10 Other studies also demonstrated that selected elderly patients could tolerate and benefit from chemotherapy. [11] [12] [13] [14] However, there are limited data describing the specific therapies for patients aged 80 years or older.
A study using the surveillance, epidemiology, and end results database from 1988 to 2003 showed that patients aged 80 years or older accounted for 14% of all patients with lung cancer. 15 In Taiwan, the proportion of patients with lung cancer aged 80 years or older increased from 7.3% in 1995 to 15 .1% in 2005. 5 However, the proportion of patient aged 70 to 79 years did not change significantly (32.5% in 1995 and 35.5% in 2005) . 5 The increase of octogenarians with lung cancer raises the importance of finding an optimal treatment for these very elderly patients.
Previously, we found that NSCLC accounted for the majority of patients with lung cancer aged 80 years or older, and most of them were stage III or IV. 16 Little is known about the treatment outcomes and prognostic factors in octogenarian with advanced NSCLC. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI), including gefitinib and erlotinib, have shown to be effective in treating NSCLC. 17, 18 A study comparing gefitinib and a placebo in patients with NSCLC refractory to chemotherapy showed a survival gain with gefitinib therapy in the subgroup of Asians. 19 Therefore, this study was to characterize the distribution and influence on outcomes of antitumor treatment modalities in octogenarians with advanced NSCLC, with a special interest in EGFR-TKI that was approved in Taiwan in 2003.
METHODS Patients
Patients with a diagnosis of lung cancer admitted to the National Taiwan University Hospital during the period between January 2000 and December 2006 were identified from a computer registration database by using the International Classification of Diseases, Ninth Revision, Clinical Modification, coding system. The patients were included if they were aged 80 years or older at diagnosis and with advanced stages of NSCLC. The diagnosis of NSCLC was based on histologic examination of biopsy specimens or on fine needle aspiration cytology. Exclusion criteria included a diagnosis of other types of cancer established before lung cancer and a clinical diagnosis without biopsy or aspiration of lung tumors. The Institutional Review Board of the National Taiwan University Hospital approved this study.
Data Collection
The medical records of all patients included were reviewed for age, gender, performance status (PS), histology of cancer, disease stages, comorbidities, history of smoking, treatment modalities, and date of death or last visit. Eastern Cooperative Oncology Group (ECOG) PS was obtained retrospectively from the charts recorded by the physicians or the nurses. The ECOG PS scores were determined by the records on admission for the patients' activity of daily life and the extent of dependence. The disease stage was determined by a combination of surgical and pathologic findings according to the current tumor, node, metastasis system for NSCLC, 20 if the patient underwent lung tumor resection. For those who did not undergo surgical intervention, clinical staging was performed according to the patients' computed tomography scan of the thorax, including the upper part of abdomen, brain computed tomography scan, and radionuclide scanning of the bone. Those with stage IIIB or IV were defined as patients with advanced stages. Histologic analysis of the tumor was based on the World Health Organization classification. 21 For initial treatment modalities, antitumor treatments included chemotherapy, palliative radiotherapy, and EGFR-TKI therapy. If the patients did not receive any antitumor treatment, they were defined as patients receiving supportive care only.
Epidermal Growth Factor Receptor Gene Mutation Analysis
We reviewed the gene epidermal growth factor receptor (EGFR) mutation status of the lung cancer specimens, whenever available, from those with EGFR-TKI therapy. In brief, DNA was derived from tumors embedded in paraffin blocks using a QIAmp DNA Mini kit (Qiagen, Valencia, CA). EGFR exons 18, 19, 20, and 21 were amplified by nested polymerase chain reaction (PCR), using specific primers. The primers and amplification conditions have been described previously. 22 The resulting PCR amplicons were purified and sequenced using the BigDye Terminator kit (Applied Biosystems, Foster City, CA) and an ABI Prism 3700 DNA Analyzer (Applied Biosystems). PCR amplicons were sequenced in both sense and antisense directions. Specimens with EGFR mutations were confirmed twice. Mutations were also checked against the single nucleotide polymorphism database.
Statistical Analysis
Patient characteristics were compared using a 2 test. Comparisons between patient groups of different PS in types of treatment were tested using a 2 method and Pearson's test. All reported p values were two sided. Survival was defined as the time between the date of diagnosis and the date of death or last visit. The patients were followed until June 30, 2008, or till the date of their death. Survival functions were analyzed by the Kaplan-Meier method. Log-rank tests were performed to compare the difference in survival between patients groups in terms of different variables. A Cox proportional hazard model was used to calculate the hazard ratio (HR) and its 95% confidence interval (CI) for age, gender, PS, histology of cancer, disease stage, smoking history, medical comorbidities, and treatment modalities. Univariate analyses were conducted to examine the unadjusted associations between patient groups with each individual independent variable. All factors significantly associated with patient survival in univariate analyses (p Ͻ 0.10) were included in the multivariate model. Variables that remained significant after multivariate adjustment were retained in the final model.
RESULTS

Clinical Characteristics
From January 2000 to December 2006, there were a total of 3639 patients with a diagnosis of lung cancer identified from the computer registration database. A total of 410 patients aged 80 years or older had histologically or cytologically proven lung cancer. Among them, 203 with advanced stages NSCLC were included.
The clinical characteristics of the 203 patients are listed in Table 1 . The median age was 83 years (range: 80 -96 years), with 114 (56.2%) male patients. There were 116 patients (57.1%) with PS 0 to 2. Eighty-three patients (40.9%) had a history of smoking, with seven (7.9% of all female patients) being women and 76 (66.7% of all male patients) men. Hypertension (56.7%) was the most common comorbidity, followed by heart disease (24.1%), including congestive heart failure and coronary artery disease, diabetes mellitus (19.8%), chronic obstructive pulmonary disease (COPD) (13.3%), renal insufficiency (creatinine Ͼ1.5 mg/dl at diagnosis) (12.3%), and diseases of the central nerve system (5.5%), including dementia and previous stroke.
For histologic distribution, adenocarcinoma (69.0%) was the most frequent histologic type. Female patients had a greater proportion of adenocarcinoma (women versus men, 85.4% versus 56.1%, p Ͻ 0.001) and a smaller proportion of squamous cell carcinoma (4.5% versus 29.0%, p Ͻ 0.001). There were 57 patients (28.1%) with stage IIIB and 146 patients (71.9%) with stage IV disease.
Treatment Modality
Among the 203 patients, 93 (45.8%) received supportive care only. Regarding the initial antitumor therapy, 65 patients (32.0%) received EGFR-TKI therapy, 17 (8.4%) received chemotherapy, and 28 (13.8%) received palliative radiotherapy ( Table 1 ). The distribution of treatment modalities in different time periods is demonstrated in Table 2 Among the 65 patients with EGFR-TKI therapy, 60 received gefitinib therapy, and five received erlotinib therapy. Among the 17 patients receiving chemotherapy, 14 received monotherapy, including 10 with gemcitabine, two with vinorelbine, and two with paclitaxel. Three patients received combination regimens, including two with vinorelbine plus cisplatin and one with gemcitabine plus vinorelbine. For the 28 patients who received palliative radiotherapy, three received whole brain radiotherapy, three for bone metastasis, and 22 for palliation of thoracic tumors.
We investigated the correlation between the PS and the treatment modalities (Table 3) . For the patients with PS 0 to 2, 42 (36.2%) received only supportive care, and 51 patients (58.6%)with PS 3 to 4 received only supportive care (p ϭ 0.002). The patients with PS 0 to 2 were more likely to receive palliative radiotherapy (PS 0 -2 versus 3-4, 19.0% versus 6.9%, p ϭ 0.014) and chemotherapy (PS 0 -2 versus 3-4, 12.9% versus 2.3%, p ϭ 0.007) than those with PS 3 to 4. The proportion of patients receiving EGFR-TKI was similar in both PS subgroups (PS0 -2 versus 3-4, 31.9% versus 32.2%, p ϭ 0.965). Figure 2 ). Concerning the survival difference in patient groups of various treatment modalities, we found the median survival was 58 days in patients who received supportive care only and 148 days in patients who received any one of the antitumor therapies (p Ͻ 0.001, Figure 3 ). The median survival was 115 days for patients who received palliative radiotherapy, 156 days for patients who received chemother-apy, and 222 days for those who received EGFR-TKI therapy. No statistically significant difference was found among the median survival of these three patient groups (p ϭ 0.76).
Survival and Prognostic Factors
By univariate analysis, we found that male gender, poor PS (PS 3-4), ever smoker, COPD, and renal insufficiency were associated with a poor survival (Table 4 ). By multivariate analysis, poor PS (HR: 2.15, 95% CI: 1.56 -2.98) and male gender (HR: 1.59, 95% CI: 1.16 -2.17) were found to be significantly associated with a worse prognosis than their counter part (Table 5 ). Patients who received EGFR-TKI therapy had a better survival than those who received supportive care only (HR: 0. 56, 95% CI: 0.40 -0.80). There was no significant survival difference in patients who received chemotherapy or radiotherapy compared with those who received supportive care ( Table 5 ).
The Association Between EGFR Mutation and Overall Survival in Patients Treated with EGFR-TKI
Among the 65 patients with EGFR-TKI therapy, there were 25 with lung cancer specimens for EGFR mutation analysis. Some of the patients were included in our previous study. 23 EGFR mutations were found in 13 patients (52.0%), including seven L858R, one L858RϩT790M, one G719D, and four exon 19 deletions. Among the patients with EGFR mutation, there were 10 women (10 of 18, 55.6%) and three men (3 of 7, 42.9%) (p ϭ 0.568). A total of 12 patients (92.3%) with EGFR mutation were adenocarcinoma (p ϭ 0.109). No significant difference was found between ever smokers and nonsmokers in the frequency of EGFR mutation Divergence between the curves representing the two groups of patients is evident, with survival time for patients with supportive care significantly shorter as determined by logrank test (antitumor therapy versus supportive care, 148 versus 58 days, p Ͻ 0.001).
(4 of 6, 66.7% versus 9 of 19, 47.4%, p ϭ 0.409). Because the tumor with T790M mutation may be resistant to EGFR-TKI therapy, we excluded the patient with L858RϩT790M while performing survival analysis. 24 Patients with EGFR muta-tions had a longer survival than those without EGFR mutations (with versus without mutation, 425 versus 183 days). However, the survival difference is not statistically significant (p ϭ 0.086, Figure 4 ).
DISCUSSION
Our study demonstrated a decrease in the proportion of supportive care and an increase in median survival after the introduction of EGFR-TKI in 2003 for octogenarian with advanced NSCLC. Patients who received EGFR-TKI therapy had a better survival than those who received supportive care only. PS 3 to 4 and male gender were significantly associated with a poor prognosis.
Few reports have described the distribution of treatment modalities in octogenarian with advanced NSCLC. A population-based study for octogenarian with NSCLC demonstrated that only 21% with stage III received the recommended therapy and 16% with stage IV received chemotherapy. 25 Another study included 70 octogenarians with stage III or IV NSCLC and showed that 36% received chemotherapy and 27% received oral target therapy alone. 26 Our study demonstrated a relatively high proportion of supportive care (45.8%) and a low proportion of chemotherapy (7.9%). The fear of side effects of chemotherapy might be the major reason to choose supportive care.
After EGFR-TKI, a more tolerable systemic therapy was introduced in 2003, and the treatment pattern changed. The proportion of supportive care decreased significantly, whereas the proportion of chemotherapy and radiotherapy changed little. The median survival increased after 2003. A recent study in Japan also showed that overall survival was FIGURE 4. Survival analysis for patients receiving epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy with EGFR mutation (n ϭ 12) and without EGFR mutation (n ϭ 12). Divergence between the curves representing the two groups of patients is not statistically evident, with survival time for patients without EGFR mutation shorter as determined by log-rank test (with versus without mutation, 425 versus 183 days p ϭ 0.086). longer for patients with advanced lung adenocarcinoma after gefitinib approval, especially for patients with EGFR mutations. 27 In this hospital-based study, we demonstrated the introduction of EGFR-TKI therapy was associated with the survival improvement for Taiwanese octogenarian with advanced NSCLC. Further population-based studies might be warranted.
Few studies reported on the treatment efficacy of EGFR-TKI in the elderly patients. A subgroup analysis in BR. 21 study showed that elderly patients treated with erlotinib had similar gains in survival and quality of life as younger patients. 28 A phase II trial of chemo-naive elderly patients (n ϭ 80) treated with erlotinib for advanced NSCLC showed a median time to progression of 3.5 months and a median survival of 10.9 months. 29 Another phase II trial with gefitinib treatment for chemo-naive patients with NSCLC aged 75 years or older showed a median survival of 10 months. 30 One study comparing gefitinib with vinorelbine in chemo-naive patients with NSCLC showed no statistical difference in efficacy, but there was better tolerability with gefitinib. 31 Using multivariate analyses, our study showed a survival benefit for octogenarians received EGFR-TKI than those who received supportive care. Further prospective large-scale randomized trials are warranted to compare EGFR-TKI with chemotherapy in elderly patients, especially for octogenarians.
A deletion in exon 19 and the exon 21L858R mutation of EGFR have been shown to predict good treatment response for EGFR-TKI. [32] [33] [34] [35] [36] Some studies have also demonstrated the association between EGFR mutation and good clinical outcome in patients with NSCLC treated with gefitinib. 23, 33, 37, 38 However, there has been little discussion regarding EGFR mutations and survival in elderly patients. Jackman et al. 29 reported that EGFR mutation was strongly correlated with disease control, prolonged time to disease progression, and survival in elderly patients treated with erlotinib. 29 However, the case number is small (n ϭ 9, aged 70 -79 years). Ebi et al. 30 also showed a better treatment response in elderly patients with NSCLC treated with gefitinib. A more recent phase II study demonstrated a median survival of 17.8 months in patients with NSCLC with poor PS or old age, who had EGFR mutation and received gefitinib therapy as the initial treatment. 39 Our study is the first study to focus on EGFR mutations in octogenarians with NSCLC. For those who received EGFR-TKI therapy, the survival is longer for those with EGFR mutation compared with those without EGFR mutation, although the difference is not statistically significant. Because elderly patients may have less chance to receive the second-line treatment than younger patients because of the likely deterioration of PS and the intolerance of treatment-related toxicities, EGFR mutations might be an important prognostic factor, especially for octogenarians with advanced NSCLC.
Although previous trials for elderly patients have demonstrated the benefits of chemotherapy on survival and quality of life, 11,40 -42 very few data have been reported regarding patients aged 80 years or older. A retrospective study demonstrated that during the period from 1997 to 2004, patients with advanced NSCLC older than 80 years (n ϭ 46) received systemic therapy, including 20 who received platinum-based chemotherapy. The response rate, median progression free survival, overall survival, and toxicity were similar for patients aged older than 80 years and aged 80 years or less. 43 In the age-specific subset analysis of trial ECOG 1594 (n ϭ 1139) for NSCLC, only nine patients were aged 80 years or older. These patients had a shorter time to progression and survival than that of the patients aged 70 to 79 years, with only one being able to receive three cycles of chemotherapy. 44 Another recent study for octogenarian with NSCLC (n ϭ 20) showed a median survival of 10 months with an acceptable toxicity profile. 45 Our study failed to demonstrate a statistically survival benefit for patients received chemotherapy (n ϭ 17), which may be due to small patient number. These octogenarians in clinical trials were all with good PS, hematological, liver, and renal function. They might represent only a small proportion of octogenarians. Whether systemic chemotherapy can be beneficial for octogenarians with advanced NSCLC requires further large-scale prospective investigations.
The clinical characteristics of our study population, a cohort of Asian patients, are different from those of white patients. There is only 13% of patients who had COPD. However, a recent report in the Netherlands had shown that 30% of male and 25% of female elderly patients with NSCLC had COPD. 46 Only 41% of our patients had a history of smoking, which is different from a cohort of octogenarians with NSCLC in the United States. 26 In that report, 91% of patients had a history of smoking. These differences may be due to the high proportion of nonsmoker in female patients (92%) in our study. Because Asian series of patients are quite different from white, conclusions from Asian studies cannot be fully applied to white patients.
Comorbidity has been demonstrated as a prognostic factor in the previous reports. A recent study showed that Charlson comorbidity index score м1, a validated measure of patient comorbidity that is weighted according to the influence of comorbidity on overall mortality, could be associated with a poorer survival for patients with NSCLC. 47 Another study by Colinet et al. 48 demonstrated that Simplified Comorbidity Score, a more informative scoring system including only seven variables, could be of prognostic value in patients with NSCLC. In our study, some comorbidities are shown to be associated with poorer prognosis in univariate analysis, such as COPD and renal insufficiency. However, these comorbidities were not associated with a poorer outcome in multivariate analysis. In this study, because of retrospective design, the comorbidity scores could not be determined for all patients. Because octogenarians frequently have multiple comorbidities, a prospective evaluation of the comorbidity scores for predicting the prognosis in octogenarians with NSCLC is warranted.
Gender was demonstrated as an independent prognostic factor, which is compatible with the results in our previous study. 16 Previous population-based studies have demonstrated a favorable outcome in women. 49 -51 However, the cause of a better prognosis in females regardless of staging and treat-ment modalities remains unclear. Recently, there have been studies on the association between estrogen receptor (ER) expression and lung cancer prognosis. In NSCLC, the expression of ER-alpha may be associated with a worse prognosis, whereas ER-beta overexpression could be a significantly favorable prognostic factor. [52] [53] [54] However, the hormone status in both genders of such elderly patients might be similar. There might be other factors associated with the survival difference between genders for patients aged 80 years or older.
There are several limitations in our study. First, this is a retrospective study. The patients included might represent a small proportion of octogenarians with NSCLC who had clinical conditions good enough to establish a histologic or cytologic diagnosis. The patient number may be underestimated. Second, the data including the dose and adjustment during treatment including EGFR-TKI and chemotherapy were not available. Third, the case numbers in the patient groups of palliative radiotherapy and chemotherapy were small for subgroup analyses. The data should be interpreted carefully. Fourth, the PS of the patients was retrospectively evaluated by medical records. The ECOG PS scores were determined by the record on admission for the patients' activity of daily life and the extent of dependence. The number of patients with PS 3 to 4 might be underestimated if the patients' condition deteriorated rapidly before cancer treatment.
In conclusion, for octogenarians with advanced NSCLC, EGFR-TKI may play an important role in the initial treatment modalities. When compared with supportive care, EGFR-TKI therapy provides a survival benefit. Further elderly specific clinical trials for octogenarian with EGFR-TKI are warranted.
